Incidence of Invasive Aspergillosis Among Allogeneic Hematopoietic Stem Cell Transplant Patients Receiving Voriconazole Prophylaxis

Diagn Microbiol Infect Dis. 2006 Jul;55(3):209-12. doi: 10.1016/j.diagmicrobio.2006.01.018. Epub 2006 Apr 19.

Abstract

We performed a retrospective observational study to examine the incidence of invasive aspergillosis (IA) among allogeneic hematopoietic stem cell transplant (HSCT) recipients, according to whether patients received at least 1 week of voriconazole prophylaxis. We report no cases of IA among 92 HSCT recipients who received voriconazole prophylaxis compared with a 10% (23/223) incidence among those receiving other systemic antifungals for prophylaxis (P < .0005).

MeSH terms

  • Adult
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / epidemiology
  • Aspergillosis / prevention & control*
  • Chi-Square Distribution
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Incidence
  • Middle Aged
  • Pyrimidines / therapeutic use*
  • Retrospective Studies
  • Transplantation, Homologous
  • Triazoles / therapeutic use*
  • Voriconazole

Substances

  • Antifungal Agents
  • Pyrimidines
  • Triazoles
  • Voriconazole